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Abstract
Human Papilloma Virus (HPV) is the etiologic agent for cervical cancer. Yet, infection with HPV is not sufficient to cause
cervical cancer, because most infected women develop transient epithelial dysplasias that spontaneously regress.
Progression to invasive cancer has been attributed to diverse host factors such as immune or hormonal status, as no
recurrent genetic alterations have been identified in cervical cancers. Thus, the pressing question as to the biological basis
of cervical cancer progression has remained unresolved, hampering the development of novel therapies and prognostic
tests. Here we show that at least 20% of cervical cancers harbor somatically-acquired mutations in the LKB1 tumor
suppressor. Approximately one-half of tumors with mutations harbored single nucleotide substitutions or microdeletions
identifiable by exon sequencing, while the other half harbored larger monoallelic or biallelic deletions detectable by
multiplex ligation probe amplification (MLPA). Biallelic mutations were identified in most cervical cancer cell lines; HeLa, the
first human cell line, harbors a homozygous 25 kb deletion that occurred in vivo. LKB1 inactivation in primary tumors was
associated with accelerated disease progression. Median survival was only 13 months for patients with LKB1-deficient
tumors, but .100 months for patients with LKB1-wild type tumors (P=0.015, log rank test; hazard ratio=0.25, 95%
CI=0.083 to 0.77). LKB1 is thus a major cervical tumor suppressor, demonstrating that acquired genetic alterations drive
progression of HPV-induced dysplasias to invasive, lethal cancers. Furthermore, LKB1 status can be exploited clinically to
predict disease recurrence.
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Introduction
Cervical cancer is among the most common cancers worldwide,
with over 500,000 new cases and 250,000 deaths each year. In the
developing world, cervical cancer is the leading cause of cancer
deaths in women [1]. Infection of cervical epithelial cells with a
transmissible agent—the Human Papilloma Virus (HPV)—is
necessary for the development of cervical cancer, as HPV DNA
sequences are detectable in .99% of cervical tumors [2,3].
Infection with ‘‘high-risk’’ HPV subtypes initiates tumor progres-
sion by abrogating cell cycle control and apoptosis checkpoints
through the viral oncoproteins E6 and E7, which inactivate the
p53 and RB tumor suppressor pathways respectively [2]. This
leads to the formation of noninvasive (in situ) cervical dysplasias
known as High-grade Squamous Intraepithelial Lesions, or HSILs)
[3,4,5]. However, these HPV-induced dysplasias are asymptom-
atic and most regress, demonstrating that HPV is not sufficient to
result in cervical cancer [2]. The progression of cervical dysplasias
to invasive, lethal cervical cancers has been attributed to diverse
factors such as immune, hormonal, and nutritional status, or co-
infection with other sexually-transmitted agents, but supporting
data have been equivocal [2]. Insertional mutagenesis by HPV is
another proposed tumor-promoting mechanism, but recent studies
have not supported this hypothesis [6]. No common, recurring
genetic alterations that cooperate with HPV to promote cervical
cancer progression have been identified since Harald Zur Hausen
first identified HPV as the causal transmissible agent of cervical
cancer over thirty years ago [7]. Thus, the pressing question as to
the biological basis of cervical cancer progression has remained
unresolved.
Germline mutations in the LKB1 tumor suppressor gene (a.k.a.
STK11) result in Peutz-Jeghers Syndrome (PJS), a hereditary
condition characterized by benign gastrointestinal polyps and an
elevated (.156) risk of malignant epithelial cancers at various
PLoS ONE | www.plosone.org 1 April 2009 | Volume 4 | Issue 4 | e5137anatomic sites [8]. The LKB1 gene was recently shown to undergo
somatic mutation in .30% of non-small cell lung cancers [9,10],
suggesting that LKB1 may play a broad tumor suppressor role.
This, combined with our recent findings that Lkb1 inactivation in
mouse uterus or epidermis promotes aggressive endometrial and
squamous cell carcinomas [11,12] prompted us to explore the role
of LKB1 in cervical cancer progression.
Results
Somatically-Acquired LKB1 Mutations are Common in
Cervical Cancer Across Histologic Subtypes
Sequencing of the LKB1 gene in primary cervical tumors
identified somatically-acquired (non-germline) mutations in 8/86
(9%) samples (Table 1, Table S1, Figure 1A). In addition to
other findings presented below, several observations argue that
these mutations are as a group inactivating, bona fide cancer-
causing mutations. First, 4/8 tumors harbored nonsense
mutations, deletions, or insertions resulting in frameshift and
premature termination. The remaining four tumors harbored
kinase domain mutations in residues conserved in vertebrate
species, and two of these tumors harbored a known PJS mutation
(p.Arg304Trp) that abrogates LKB1 kinase activity [13,14,15].
Lastly, only 1/9 coding variants were of germline origin, vs. 7/7
noncoding variants, a difference that is statistically significant
(p=0.0014, Fisher’s Exact Test) particularly since the single
germline coding variant c.2077C.G (p.Phe354Leu) is a known
non-pathological neutral variant present in normal individuals
[16]. Sequencing also identified a homozygous LKB1 kinase
domain mutation in the cervical cancer cell line C4I (Figure 1B,
Table S1).
Although one small (26 bp) LKB1 deletion representing a
complete loss-of-function was identified by sequencing (Table S1,
Figure 1A), larger deletions would have been missed. To
systematically screen for deletions, multiplex ligation-dependent
probe amplification (MLPA) for all 10 LKB1 exons and three
flanking probes was employed. Whereas normal human DNA
control samples (n=3) consistently showed equivalent signal
strengths for all probes, MLPA identified distinct LKB1 deletions
in 10/86 tumors (Table S1, Figure 1C). In five tumors, deletions
appeared to be homozygous because signals from contiguous
probes were reduced by .50% (Figure 1C, cases 60 and 22);
residual signal in these cases likely reflects stromal contamination.
Of tumors with apparent heterozygous deletions, one also
contained a significant mutation identified by sequencing (Case
41, which harbors a 26 bp deletion, Table S1). These findings are
consistent with human and mouse studies showing that although
loss of the second allele can accelerate tumor progression,
mutation of a single LKB1 allele is by itself tumorigenic (i.e.
LKB1 can be haploinsufficient) [9,17]. However, it is also possible
that some mutations went undetected, or that stromal contami-
nation led to an underestimation of homozygosity. In summary,
biologically-significant LKB1 mutations including deletions char-
acterize at least 20% (17/86) of invasive cervical cancers. Only one
case in our study (case 20, which harbored a somatically-acquired
LKB1 mutation) was diagnosed as a minimal-deviation adenocar-
cinoma (MDA), a rare, extremely well-differentiated variant of
cervical adenocarcinoma associated with Peutz-Jeghers Syndrome
[18]. Thus, LKB1 mutations in cervical cancers were not limited to
this rare histologic subtype but were present across the principal
histologic subtypes of cervical cancer—adenocarcinoma, squa-
mous cell carcinoma, and adenosquamous carcinoma (Figure 2,
Table S1) [4].
Deletions of LKB1 Characterize Most Cervical Cancer Cell
Lines
Primary tumors are clonally diverse and contain variable
numbers of cells such as fibroblasts and lymphocytes that can
obscure these and other analyses. To overcome this limitation and
gain further insights into the role of LKB1 in cervical cancer, a
panel of seven cervical cancer cell lines (HeLa, HT3, SiHa,
MS751, CaSki, C33a, and C4I) was analyzed. Strikingly, five of
these seven cell lines harbored LKB1 deletions, as did the HeLa
derivative HeLaS3 (Figure 3A). Only the CaSki (Figure 3A) and
C33a (not shown) cell lines did not exhibit LKB1 deletions. The
majority (4/7) harbored homozygous deletions, while the one cell
line with a heterozygous deletion (C4I) also harbored a point
mutation (Figure 1B, Table S1) rationalizing the loss of
heterozygosity for this mutation in C4I. Southern analysis
confirmed loss of LKB1 sequences (Figure 3B) and as expected,
LKB1 protein was undetectable in the cell lines harboring
homozygous deletions (Figure 3C). This frequent homozygosity
of LKB1 mutations in cell lines further underscores the
pathogenetic significance of LKB1 loss in cervical cancer. Although
the number of lines available and hence analyzed was small, it is
notable that the majority of cervical cancer cell lines harbored
definitive bialleleic LKB1 mutations. It is also possible that the
establishment of primary cervical tumor cultures is biased towards
LKB1-deficient tumors.
The absence of LKB1 protein in HeLa and HeLaS3 has been
previously noted [19]. The LKB1 gene is associated with a
prominent CpG island, and the lack of LKB1 protein and
mRNA in HeLa cells had been previously attributed to promoter
hypermethylation [20]. However, we found no evidence of LKB1
hypermethylation by methylation-specific PCR in any cell line or
primary tumor samples. To the contrary, our data show that
HeLa and other cervical cancer cell lines do not express LKB1
because of homozygous deletions, rather than as a result of
Table 1. Characteristics of 86 Patients in the Study
Population.
Age—yr
Median 46
Mean 47.1
Range 24–88
Histology—number (%)
Adenocarcinoma 22 (26)
Adenosquamous 7 (8)
Squamous 57 (66)
Stage—number (%)
I2 5 ( 2 9 )
II 36 (42)
III 15 (17)
IV 7 (8)
Unknown 3 (4)
Grade—number (%)
1 3 (4)
25 7 ( 6 6 )
31 8 ( 2 1 )
Ungraded 8 (9)
doi:10.1371/journal.pone.0005137.t001
LKB1 and Cervical Cancer
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HeLa [19] and other cell lines [9], enforced expression of wild-
type LKB1 led to cell cycle arrest and growth inhibition,
demonstrating that LKB1 loss in these cell lines is functionally
significant (data not shown).
To define deletion breakpoints, PCR reactions producing small
amplicons (100–200 bp) were designed to span the locus
(Figure 4A, B). Scoring (+/2) amplification of each product
followed by additional PCR reactions for progressively narrower
intervals based on results of the initial scan permitted us to map
breakpoints to within a few kb (Figure 4C). Each of the four cell
lines harbored a distinct deletion (,20–110 kb) removing portions
of LKB1 and at most one other flanking locus (SBNO2).
Molecular Cloning of the HeLa LKB1 Deletion Junction
and In Vivo Origin of the Deletion
To clone across the HeLa junction, primers flanking the 59 and
39 breakpoints mapped by the above PCR scanning strategy were
designed to amplify a specific breakpoint product. A 2.8 kb
junctional fragment was cloned and sequenced, confirming the
presence of a deletion (24,662 bp, Figure S1, Figure 4C). Both
breakpoints lie within Alu repeats (Figure S1), suggesting that
inter-Alu homologous recombination produced the deletion. To
create an efficient PCR assay for this deletion, primers
immediately flanking the repetitive Alu sequences at each
breakpoint were designed (400 bp) (Figure S1).
HeLaS3, a clonal derivative of HeLa first reported in 1955 [21],
harbored the identical LKB1 deletion (Figure 4D), establishing
1955 as a terminus ante quem for the origin of the deletion. However,
it remained formally possible that the LKB1 deletion arose in vitro
following the establishment of HeLa from a primary cervical
adenocarcinoma in 1951 [22]. To resolve this question, HeLa
tumor DNA was isolated from an archival paraffin-embedded
tissue block prepared in the course of the patient’s autopsy at the
Johns Hopkins Hospital in 1951. A 400 bp HeLa-specific PCR
product was amplified from the tumor (Figure 4E), establishing
that the LKB1 deletion occurred in vivo.
The occurrence of the LKB1 HeLa deletion while the patient
was alive suggested that LKB1 inactivation might have contributed
to the notoriously aggressive growth of her tumor both in vivo and
in vitro (see below and discussion). To explore the possibility that
LKB1 mutations influence disease course, progression-free survival
curves were generated for patients whose tumors harbored LKB1
mutations identified by sequencing or MLPA (heterozygous or
Figure 1. Somatic mutations and deletions of LKB1 in cervical tumors. (A) Representative chromatograms of primary tumors. (B) C4I cell line.
Lower panels, control DNA samples from each patient (for C4I, human peripheral leukocyte DNA). Wild-type sequences are shown below.
Chromatograms represent forward strand except case #41 where reverse complement is shown to more clearly illustrate the deletion. Mutations are
heterozygous except where indicated. (C) LKB1 deletions in primary cervical tumors by MLPA. Bars=relative signal intensity per probe. Sixteen probes
(black) correspond to LKB1 locus on chromosome 19. Probe identifiers shown below. Probes 0.9M59 and 0.6M59 are ,900 and 600 kb 59 of locus
(telomeric), while 10M39 is ,10000 kb 39 (centromeric); remaining 13 probes correspond to LKB1 noncoding/coding exons. White bars correspond to
randomly selected probes from other chromosomes.
doi:10.1371/journal.pone.0005137.g001
LKB1 and Cervical Cancer
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Strikingly, the median survival was only 13 months for patients
with LKB1-deficient tumors, but .100 months for patients with
LKB1-wild type tumors (Figure 5) (P=0.015, log-rank test; hazard
ratio=0.25, 95% CI=0.083 to 0.77). LKB1-deficient tumors were
not more advanced at the time of staging, e.g., 28% of LKB1-wild
type tumors were initially Stage I (confined to the uterus), vs. 43%
for LKB1-deficient tumors, nor of higher grade (i.e. more poorly-
differentiated). Thus, LKB1 mutations in cervical tumors confer a
stage-for-stage increased risk of recurrence, suggesting that assays
of LKB1 status will be of clinical utility in identifying patients at
increased risk for disease progression.
Discussion
Our study is the first to demonstrate that recurrent genetic
mutations occur in cervical cancer. An earlier study that examined
this question did not identify LKB1 mutations in sporadic cervical
cancers, but only minimal deviation adenocarcinomas were
analyzed, as the goal of the study was to ascertain LKB1 mutation
frequencies in gynecologic malignancies known to be associated
with PJS. However, this earlier study, performed prior to the
advent of MLPA, identified LOH of the LKB1 19p13.3 region in
3/8 cases, suggesting that LKB1 deletions may have been present
[23]. Another study where 26 cervical tumors were analyzed by
single-strand conformational polymorphism analysis identified
LKB1 mutations in only one case [24]. However, this study also
greatly underestimated the frequency of LKB1 mutations in lung
cancer, now known to occur in .20% of cases. The advent of
MLPA now facilitates the definitive identification of LKB1
deletions, which account for ,50% of mutations in lung and
cervical cancer (this and other studies) [9]. Another factor
potentially obscuring prior sequence analyses is the unusually
high GC content of LKB1 exonic regions. In our experience,
automated base call software overlooked a high percentage of
mutations, necessitating direct inspection of chromatograms.
The discovery of a homozygous LKB1 deletion in HeLa is
noteworthy because of the historical significance of this cell line to
biomedical research. HeLa was derived in 1951 from a cervical
adenocarcinoma. As the first immortalized human cell line isolated
and successfully perpetuated in vitro, HeLa greatly accelerated the
progress of biomedical research in the second half of the 20
th
century [25]. HeLa cells were unusual in growing so rapidly in
culture, but the primary tumor was also aggressive. The primary
tumor was confined to the cervix at the time of diagnosis, but it
metastasized early and widely despite aggressive therapy including
radiation treatment, leading to the patient’s death just six months
after the initial diagnosis [26,27,28]. Our results suggest that the
homozygous deletion we have documented within LKB1 contrib-
uted to this aggressive growth phenotype, rationalizing some of the
unusual features of the HeLa primary tumor and cell line.
Consistent with this idea, enforced expression of LKB1 cDNA into
HeLa and other HeLa-deficient cell lines induces growth arrest
(unpublished data, see also [9,19]).
This is also the first report that LKB1 mutations confer a worse
prognosis for a particular human cancer. However, this observa-
tions is in line with genetically-engineered mouse models of LKB1
deficiency that have consistently found that Lkb1 loss promotes
invasive/metastatic growth. In K-ras driven mouse models of lung
cancer, Lkb1 inactivation provided the strongest cooperation in
terms of tumor latency and frequency of metastasis (as compared
to classic tumor suppressors such as p53 and Ink4a/Arf). It is also
notable that Lkb1 loss in the lung was associated with a broad
histologic spectrum (squamous cell carcinomas to adenocarcino-
mas), recalling that LKB1 inactivation characterizes cervical
carcinomas of varied histologic subtypes [9]. Similarly, mice with
targeted inactivation of Lkb1 in endometrial epithelium develop
highly invasive (yet paradoxically extremely well-differentiated)
endometrial adenocarcinomas [11]. Taken together, these and
other results [12,29] argue that LKB1 suppresses invasion and
metastasis and suggest that assays based on LKB1 may prove
useful for prognostication in a variety of cancers. It will be of
interest to determine if LKB1 mutations are also useful prognos-
tically in other cancers [9].
The fact that 99% of cervical cancers contain HPV DNA [2] as
is the case for most of the cervical cancer cell lines in which we
Figure 2. LKB1 mutations occur in each of the principal histologic subtypes of cervical cancer. (A) Histology of representative cases with
LKB1 mutations (SCC=squamous cell carcinoma; Adeno=adenocarcinoma; AdenoSq=adenosquamous carcinoma; MDA=minimal deviation
adenocarcinoma). Scale bar=20 microns. (B) Relative distribution of the three principal histologic subtypes among LKB1-mutant (red) vs. LKB1-wild
type (black) cases (totals=100%) shows that the histologic spectrum is virtually identical in LKB1 null vs. wild-type tumors.
doi:10.1371/journal.pone.0005137.g002
LKB1 and Cervical Cancer
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integrated HPV-18 sequences) [30] suggest that LKB1 and HPV
cooperate in some manner. HPV infection promotes the formation of
in situ lesions, leading us to propose that additional mutations in genes
including LKB1 are required to convert in situ dysplasias to invasive
carcinomas, an idea consistent with the diverse animal models
discussed above. Further studies i.e. with genetically-engineered
animal models will be required to understand the biological basis of
the interaction between HPV and LKB1. The biological and
biochemical basis of LKB1-mediated carcinogenesis remains to be
fully elucidated. Misregulation of the AMPK-mTOR pathway likely
contributes to LKB1’s role as a tumor suppressor, but probably does
not entirely account for its role in mediating invasion [31].
Nonetheless, misregulation of mTOR in LKB1-deficient tumors
may present opportunities for targeted therapy (e.g. through the use
of metformin or rapamycin analogs) in women whose cervical tumors
have confirmed LKB1 mutations/deletions, an idea that merits
further investigation in the future.
The biological basis of the progression of HPV-induced
precancers has been undefined. This study presents the first
definitive evidence that recurring mutations in discrete host genes
occur in invasive cervical cancer. Although other factors likely
influence progression, this study demonstrates that a process likely
to be stochastic—namely the acquisition of discrete genetic
mutations—drives progression of cervical dysplasias to invasive
lethal carcinomas and that these mutations have the potential to
serve as useful prognosticators.
Materials and Methods
Ethics Statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The study was approved by the
Institutional Review Board of the UT Southwestern and Johns
Hopkins hospitals.
Patient Samples and Cell Lines
The patients were a subgroup of patients diagnosed with
primary cervical cancer at UT Southwestern University
Hospitals between 2000–2007 and who provided informed
Figure 3. Homozygous LKB1 deletions occur in majority of cervical cancer cell lines. (A) MLPA; see Figure 1 for probe details. HeLa, MS751,
SiHa, and HT3 (and HeLa subclone HeLaS3) contain distinctive homozygous deletions. C4I harbors a monoallelic deletion, as evidenced by contiguous
probes with half-intensity signals. (B) Southern analysis of control DNA, above cell lines, C33 (no deletion by MLPA) and HPV16/E6E7-immortalized
endocervical cells from a normal patient (Endo=End1/E6E7; ATCC #CRL-2615). (C) Western analysis. LKB1 protein is undetectable in lines harboring
homozygous deletions and decreased by ,50% in C4I, consistent with monoallelic loss.
doi:10.1371/journal.pone.0005137.g003
LKB1 and Cervical Cancer
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criteria [4]. Sufficient amounts of tissue from the primary tumor
had to be available to permit the isolation of DNA for
sequencing and MLPA; otherwise there were no exclusion
criteria. For most patients, control DNA was prepared from
blood; for a small number of patients for whom blood was
unavailable, DNA was prepared from paraffin-embedded control
tissues. Tumor stage was determined per FIGO criteria. Data for
disease progression analysis per RECIST criteria were obtained
from follow-up visits. We recommended that patients have
follow-up visits every 3 months for 2 years, then every 6 months
for 3 years, and annually thereafter. For progression-free
survival, time from completion of primary therapy to recurrence
or death was recorded. Data for patients without tumor
recurrence were censored at the time of the last follow-up visit.
For the HeLa tumor study, a paraffin block was obtained from
the archives of the Johns Hopkins Hospital. Cell lines were
purchased from the ATCC.
DNA Sequencing
DNA was prepared using Qiagen genomic DNA columns. A
two step ‘‘boost/nest’’ PCR strategy was employed where the
boost reaction generated a larger fragment used as a template for
the nest reaction. The nest products were bidirectionally
sequenced on ABI 3730 XL sequencers with ABI Big Dye
Terminator 3.1 chemistry. Base calling was performed with the
Agent system (Paracel). Sequence tracings were visually inspected
to confirm accurate variant detection by the base-calling software.
PCR primer sequences/conditions are available upon request.
Coding variants were confirmed on repeat PCR reactions to
exclude PCR artifacts. Genbank NM_000455 was used as the
reference cDNA for nucleotide positions.
Multiplex Ligation Dependent Probe Amplification
(MLPA) and Southern/Western Analysis
MLPA was performed as described [9]. For Southern analysis,
10 mg genomic DNA was XbaI-digested prior to gel electropho-
resis, transferred to a membrane, and hybridized with radiola-
belled-probes (1–2 kb) generated by PCR and confirmed by end-
sequencing. The membrane was hybridized to probe A, subjected
to autoradiography, stripped in boiling 0.1% SDS, and rehybri-
dized to probe B. For Western analysis, protein extracts were
prepared from adherent cells by homogenization in lysis
buffer+protease inhibitors on ice, subjected to SDS-PAGE and
immunoblotted with an LKB1 antibody (#3047, Cell Signalling
Technology) per the manufacturer’s recommendations.
Figure 4. LKB1 deletion breakpoints in cervical cancer cell lines. (A) LKB1 locus (chromosome 19p13.3). (B) 140 kb region (Ensembl50;
1050000–1190000) spanning LKB1 and immediately flanking loci; intervals=10 kb. (C) Deletion breakpoints for cell lines harboring homozygous
deletions. In MS751, deleted sequences are discontinuous as shown, consistent with a more complex rearrangement. Arrows=PCR primers for HeLa
specific PCR (400 bp). (D) HeLa specific PCR (400 bp) confirms presence of deletion in HeLaS3. (E) HeLa intragenic LKB1 deletion occurred in vivo.
Archival blocks were cored for DNA preparation. Lanes are as follows: (2) control=no template control; tumor=metastatic adrenal deposit; non-
tumor=normal adrenal (same tissue block); (+) control=HeLa cell line DNA.
doi:10.1371/journal.pone.0005137.g004
Figure 5. Progression-free survival of patients with LKB1-wild
type vs. LKB1-mutant tumors. Kaplan-Meier curves show the
percentage of patients with disease progression over time. The curves
compare patients whose tumors were heterozygous or homozygous for
mutations/deletions (LKB1) vs. patients with no mutations/deletions
(wt). Patients with .1 follow-up visit were included in the analysis. P
value per log-rank test.
doi:10.1371/journal.pone.0005137.g005
LKB1 and Cervical Cancer
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Paraffin block 5 mm sections were deparaffinized/ hydrated in
an ethanol series. Slides were stained with H&E and mucicarmine
per standard protocols. For immunohistochemistry, slides were
subjected to antigen retrieval in boiling in 10 mM NaCitrate; p63
antibody (#MS1081, LabVision) was used at 1:400 with the
Immpress detection system (Vector).
PCR Scanning to Define Deletions and HeLa-specific PCR
PCR primers (producing 100–200 bp amplicons) spanning the
LKB1 region were designed using Primer3. Primer pairs producing
products of correct size when normal human DNA was used as
template were used to map deletions by scoring presence/absence
of amplification with cell line DNAs as template. Additional
reactions to give products corresponding to progressively smaller
intervals were designed as necessary. Primer sequences and PCR
conditions are available upon request. Archival tissue block DNA
was prepared as described [32]. Primer sequences for HeLa-
specific PCR (400 bp) were For(59-GGTTGCGAT-
CAAGGCCCCGA-39) and Rev(59-GCCTGTGGATGCCACA-
CATG-39). PCR conditions were 95C6109; 94C6300, 58C6300,
72C6300 (38 cycles); 72C679.
Statistical Analysis
For comparison of mutant frequencies, Fisher’s (two-tailed)
unpaired exact test was used. Survival curves were generated in
GraphPad Prism5, with comparison of the curves performed with
the Log-rank (Mantel-Cox) test. The hazard ratio and its
confidence interval were computed using the Mantel-Haenszel
method. P values less than 0.05 were considered to indicate
statistical significance.
Supporting Information
Figure S1 Cloning and characterization of LKB1 intragenic
deletion breakpoints in HeLa/HeLaS3. A 2.8 kb fragment
spanning the deletion breakpoint was cloned from HeLa DNA
by PCR as described in the text; 974 bp of this sequence are
shown. Sequence in bold red letters corresponds to the Alu repeat
in which the presumptive homologous recombination event
resulting in the HeLa deletion occurred. Nucleotide polymor-
phisms in the two native Alu sequences (not shown) were
consistent with a recombination event occurring within the 5 bp
boxed sequence (i.e., the flanking G bases were polymorphic and
informative). Sequence in blue corresponds to a unique sequence
in the human genome (Ensembl 50 19:1145482 to 1145865). This
sequence is ,11 kb from the 59 end of the LKB1 gene
(transcriptional start). Sequence in green (Ensembl 50
19:1170845 to 1171115) lies within LKB1 intron 3–4. The arrows
show the location of the primers designed for HeLa-specific PCR
(400 bp amplicon). The genomic location of these primers on the
genomic map is shown in Figure 4C.
Found at: doi:10.1371/journal.pone.0005137.s001 (0.01 MB
PDF)
Table S1 Complete list of LKB1 mutations detected by
sequencing or MLPA.
Found at: doi:10.1371/journal.pone.0005137.s002 (0.01 MB
PDF)
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